Spectral AI (NASDAQ:MDAI) Research Coverage Started at HC Wainwright

Equities research analysts at HC Wainwright started coverage on shares of Spectral AI (NASDAQ:MDAI) in a note issued to investors on Thursday, Benzinga reports. The firm set a “buy” rating and a $3.50 price target on the stock. HC Wainwright’s price target points to a potential upside of 83.25% from the company’s current price.

Spectral AI Trading Up 2.1 %

Spectral AI stock opened at $1.91 on Thursday. Spectral AI has a 52-week low of $1.52 and a 52-week high of $19.50. The stock has a fifty day moving average price of $1.72 and a two-hundred day moving average price of $2.02.

Spectral AI (NASDAQ:MDAI) last announced its earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share for the quarter. The firm had revenue of $6.33 million during the quarter.

Institutional Trading of Spectral AI

A number of hedge funds and other institutional investors have recently made changes to their positions in MDAI. Highlander Partners L.P. increased its position in Spectral AI by 18.6% in the fourth quarter. Highlander Partners L.P. now owns 900,000 shares of the company’s stock worth $2,214,000 after purchasing an additional 141,416 shares during the period. Murchinson Ltd. acquired a new stake in Spectral AI in the first quarter worth about $85,000. Citigroup Inc. acquired a new stake in Spectral AI in the third quarter worth about $62,000. Virtu Financial LLC acquired a new stake in Spectral AI in the first quarter worth about $38,000. Finally, Cantor Fitzgerald L. P. acquired a new stake in Spectral AI in the fourth quarter worth about $38,000. 67.08% of the stock is currently owned by institutional investors and hedge funds.

Spectral AI Company Profile

Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.